181 related articles for article (PubMed ID: 33610480)
21. Good Manufacturing Practices (GMP) manufacturing of advanced therapy medicinal products: a novel tailored model for optimizing performance and estimating costs.
Abou-El-Enein M; Römhild A; Kaiser D; Beier C; Bauer G; Volk HD; Reinke P
Cytotherapy; 2013 Mar; 15(3):362-83. PubMed ID: 23579061
[TBL] [Abstract][Full Text] [Related]
22. Mini-review: Equipment evaluation for process scalability and readiness for current Good Manufacturing Practices in cell therapy workflows.
Verbarendse M; Snyder R; Lakshmipathy U
Cytotherapy; 2023 Oct; 25(10):1107-1112. PubMed ID: 37294247
[TBL] [Abstract][Full Text] [Related]
23. Current good manufacturing practice in manufacturing, processing, packing, or holding of drugs; revision of certain labeling controls--FDA. Final rule.
Fed Regist; 1993 Aug; 58(147):41348-54. PubMed ID: 10127711
[TBL] [Abstract][Full Text] [Related]
24. Medical devices; current good manufacturing practice (CGMP) final fule; quality system regulation--FDA. Final rule.
Fed Regist; 1996 Oct; 61(195):52602-62. PubMed ID: 10168287
[TBL] [Abstract][Full Text] [Related]
25. The quest for quality blood banking program in the new millennium the American way.
Kim DU
Int J Hematol; 2002 Aug; 76 Suppl 2():258-62. PubMed ID: 12430934
[TBL] [Abstract][Full Text] [Related]
26. United States of America Department of Health and Human Services support for advancing influenza vaccine manufacturing in the developing world.
Perdue ML; Bright RA
Vaccine; 2011 Jul; 29 Suppl 1():A48-50. PubMed ID: 21684430
[TBL] [Abstract][Full Text] [Related]
27. Regulation of advanced therapy medicinal products in Europe and the role of academia.
Pearce KF; Hildebrandt M; Greinix H; Scheding S; Koehl U; Worel N; Apperley J; Edinger M; Hauser A; Mischak-Weissinger E; Dickinson AM; Lowdell MW
Cytotherapy; 2014 Mar; 16(3):289-97. PubMed ID: 24113428
[TBL] [Abstract][Full Text] [Related]
28. Variations in novel cellular therapy products manufacturing.
Fontaine MJ; Selogie E; Stroncek D; McKenna D; Szczepiorkowski ZM; Takanashi M; Garritsen H; Girdlestone J; Reems JA;
Cytotherapy; 2020 Jun; 22(6):337-342. PubMed ID: 32223996
[TBL] [Abstract][Full Text] [Related]
29. How do I structure logistic processes in preparation for outsourcing of cellular therapy manufacturing?
Chen LN; Collins-Johnson N; Sapp N; Pickett A; West K; Stroncek DF; Panch SR
Transfusion; 2019 Aug; 59(8):2506-2518. PubMed ID: 31135995
[TBL] [Abstract][Full Text] [Related]
30. Cellular manufacturing for clinical applications.
Sheu J; Klassen H; Bauer G
Dev Ophthalmol; 2014; 53():178-88. PubMed ID: 24732771
[TBL] [Abstract][Full Text] [Related]
31. A novel, flexible and automated manufacturing facility for cell-based health care products: Tissue Factory.
Kikuchi T; Kino-Oka M; Wada M; Kobayashi T; Kato M; Takeda S; Kubo H; Ogawa T; Sunayama H; Tanimoto K; Mizutani M; Shimizu T; Okano T
Regen Ther; 2018 Dec; 9():89-99. PubMed ID: 30525079
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive hands-on training for influenza vaccine manufacturing: a WHO-BARDA-BTEC partnership for global workforce development.
Ruiz J; Gilleskie GL; Brown P; Burnett B; Carbonell RG
Biochem Mol Biol Educ; 2014; 42(5):414-9. PubMed ID: 25132407
[TBL] [Abstract][Full Text] [Related]
33. Cell and gene therapy manufacturing capabilities in Australia and New Zealand.
O'Sullivan GM; Velickovic ZM; Keir MW; Macpherson JL; Rasko JEJ
Cytotherapy; 2019 Dec; 21(12):1258-1273. PubMed ID: 31806531
[TBL] [Abstract][Full Text] [Related]
34. Implementation of Current Good Manufacturing Practices in a small research laboratory setting.
Keller CD; Taulbee SM
Qual Assur; 1995 Mar; 4(1):83-6. PubMed ID: 8520870
[TBL] [Abstract][Full Text] [Related]
35. Training practices of cell processing laboratory staff: analysis of a survey by the Alliance for Harmonization of Cellular Therapy Accreditation.
Keever-Taylor CA; Slaper-Cortenbach I; Celluzzi C; Loper K; Aljurf M; Schwartz J; Mcgrath E; Eldridge P;
Cytotherapy; 2015 Dec; 17(12):1831-44. PubMed ID: 26455277
[TBL] [Abstract][Full Text] [Related]
36. Cellular Therapies Clinical Research Roadmap: lessons learned on how to move a cellular therapy into a clinical trial.
Ouseph S; Tappitake D; Armant M; Wesselschmidt R; Derecho I; Draxler R; Wood D; Centanni JM
Cytotherapy; 2015 Apr; 17(4):339-43. PubMed ID: 25484311
[TBL] [Abstract][Full Text] [Related]
37. Biological products: reporting of biological product deviations in manufacturing. Food and Drug Administration, HHS. Final rule.
Fed Regist; 2000 Nov; 65(216):66621-35. PubMed ID: 11503696
[TBL] [Abstract][Full Text] [Related]
38. Chimeric antigen receptor-T cell therapy manufacturing: modelling the effect of offshore production on aggregate cost of goods.
Harrison RP; Zylberberg E; Ellison S; Levine BL
Cytotherapy; 2019 Feb; 21(2):224-233. PubMed ID: 30770285
[TBL] [Abstract][Full Text] [Related]
39. Review of red yeast rice content and current Food and Drug Administration oversight.
Childress L; Gay A; Zargar A; Ito MK
J Clin Lipidol; 2013; 7(2):117-22. PubMed ID: 23415430
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
